BioSpace News Archive

Bicycle Therapeutics announced that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research Annual Meeting in Atlanta.

Newly-acquired Natura Naturals Inc. located in Leamington, Ontario obtains processing license, allowing it to produce a wide range of cannabis form factors for the Canadian market

New molecular platform to access intracellular targets across a broad range of tumor cell types

Six pipeline presentations profile innovative approaches being studied by Eisai and its subsidiary H3 Biomedicine, including data on structurally novel STING agonist

Jefferson Surgery Center – Blue Bell, a NueHealth facility, has achieved both three-year accreditation by the Accreditation Association for Ambulatory Health Care (AAAHC) and Medicare Deemed Status.

REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant

ClearLight Biotechnologies, LLC (formerly known as ClearLight Diagnostics, LLC) a developer of an automated next generation tissue processing and 3D image analysis platform, announced today that it will present data at the 2019 American Association for Cancer Research meeting in Atlanta, Georgia.

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that FDC has chosen ValGenesis’s 100% paperless Validation Lifecycle Management System (VLMS) to digitize and standardize its validation lifecycle process across the organization.

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2019 financial results and respond to questions from financial analysts during the call.

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today provided a corporate update and reported financial results for the year ended December 31, 2018.